Concentric Wins Full-Service Professional Assignment From Biopharm Innovato...( NEW YORK July 8 /- Concentric Pha...)

NEW YORK, July 8 /PRNewswire/ -- Concentric Pharma Advertising, Inc., a five-year-old independent agency and one of the fastest growing in the field, has been selected by biopharmaceutical company Neuromed for U.S. professional communications supporting a developmental once-daily medication for the treatment of chronic pain.

The full-service assignment will include a broad range of activities, including branding, launch planning, marketing strategy, the creation of graphics and other support materials, and all tactical execution

Neuromed is a biopharmaceutical company focused on developing new and improved pain therapies. Concentric will work with the company on its most advanced program, the development of an extended-release formulation of a potent and widely used pain reliever that currently requires several doses daily for optimal effectiveness. Founded in Canada in 1998, Neuromed conducts its clinical and commercial operations from an office in the Philadelphia region. The company's research and financial operations are based in Vancouver, British Columbia.

"After an extensive review of 14 agencies, we selected Concentric for this assignment on the strength of its strategic and creative approach to the launch of our product," said Sean Cunliffe, Chief Commercial Officer of Neuromed.

Mario Orlando, vice president of marketing, will oversee the account from the client side. Tim Campbell, director of client services at Concentric, will manage the business on the agency side. Spending has not been disclosed.

About Concentric

Concentric Pharma Advertising, an independent healthcare advertising and marketing agency established in 2002, helps clients meet diverse business objectives through innovative thinking, elegant creative strategies, results-oriented tactics, and flawless execution.

The company is one of the fastest growing agencies in the healthcare field. In the past year alone, Concentric has tripled its
'/>"/>